Table 1.
Clinicopathological characteristics of study patients
| No. of patients (n = 20) |
|
|---|---|
| Age (years), median (i.q.r.) | 44 (35–51) |
| BRCA mutation | |
| ȃNo | 11 |
| ȃBRCA1 | 3 |
| ȃBRCA2 | 1 |
| ȃUnknown | 5 |
| cT category | |
| ȃcT1 | 2 |
| ȃcT2 | 15 |
| ȃcT3 | 3 |
| cN category | |
| ȃcN0 | 5 |
| ȃcN1 | 15 |
| Subtype | |
| ȃTriple-negative | 17 |
| ȃHER2+ | 3 |
| Hormone therapy | |
| ȃNo | 16 |
| ȃLHRH agonists | 4 |
| Side | |
| ȃRight | 10 |
| ȃLeft | 10 |
| Surgery | |
| ȃNipple-sparing mastectomy + SLN biopsy | 7 |
| ȃQuadrantectomy + SLN biopsy | 13 |
| No. of SLNs removed, median (range) | 3 (1–11) |
HER2, human epidermal growth factor receptor 2; LHRH, luteinizing hormone-releasing hormone; SLN, sentinel lymph node.